Prezista Related Published Studies
Well-designed clinical trials related to Prezista (Darunavir)
Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. [2009.09.10]
Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. [2008.10.01]
Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir. [2008.10.01]
[Darunavir as first-line therapy. The TITAN study] [2008.10]
[Darunavir in treatment-naive patients. The ARTEMIS study] [2008.10]
Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. [2008.08]
Resistance profile of darunavir: combined 24-week results from the POWER trials. [2008.03]
Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. [2008.01]
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. [2007.07.07]
Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. [2007.07]
Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA. [2007.05]
Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. [2007.03]
Well-designed clinical trials possibly related to Prezista (Darunavir)
Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. [2009.04]
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. [2008.07.24]
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. [2007.07.07]
TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. [2005.06.10]
Other research related to Prezista (Darunavir)
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. [2009.11.01]
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. [2009.09.24]
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. [2009.08.24]
Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study. [2009.07.31]
Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial. [2009.07.06]
Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients. [2009.07]
Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. [2009.05]
Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. [2009.04]
Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection. [2009.03.17]
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. [2009]
Darunavir: a review of its use in the management of HIV infection in adults. [2009]
Use of darunavir and enfuvirtide in a pregnant woman. [2008.12]
Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study. [2008.12]
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. [2008.11]
Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naive and -experienced patients. [2008.11]
Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2. [2008.10]
[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies.] [2008.10]
Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen. [2008.09.12]
Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases. [2008.09]
New therapeutic agents in the management of HIV: an overview of darunavir for clinicians. [2008.09]
Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine. [2008.08]
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. [2008.07.31]
Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. [2008.07]
A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells. [2008.04.11]
Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. [2008.03.12]
Experience with darunavir in HIV-infected adults enrolled in a US expanded access program: results from a single center. [2008.03]
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir. [2008.02]
Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. [2008]
Effect of Repeated Doses of Darunavir plus Low-Dose Ritonavir on the Pharmacokinetics of Sildenafil in Healthy Male Subjects : Phase I Randomized, Open-Label, Two-Way Crossover Study. [2008]
Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). [2008]
Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1. [2008]
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. [2007.12.15]
Pharmacokinetic Interaction Between Darunavir and Saquinavir in HIV-negative Volunteers. [2007.12]
Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. [2007.10.15]
Darunavir. [2007.10]
Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. [2007.10]
Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. [2007.09.01]
Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trials. [2007.09]
Darunavir: A second-generation protease inhibitor. [2007.08.01]
Darunavir (TMC114): a new HIV-1 protease inhibitor. [2007.08]
Darunavir: a nonpeptidic antiretroviral protease inhibitor. [2007.08]
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. [2007.07.11]
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients. [2007.05.31]
Analysis of Treatment Costs for HIV RNA Reductions and CD4 Increases for Darunavir Versus Other Antiretrovirals in Treatment-Experienced, HIV-Infected Patients. [2007.05]
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. [2007.04.07]
The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. [2007.04]
Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance. [2007.03]
Pharmacokinetics of Darunavir (TMC114) and Atazanavir during Coadministration in HIV-Negative, Healthy Volunteers. [2007]
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. [2007]
Clinical pharmacokinetics of darunavir. [2007]
Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. [2007]
Other possibly related research studies
Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance. [2006.12]
Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors. [2006.07.13]
[New drugs--hope for salvage patients?] [2005.04.25]
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. [2007.02.19]
The latest in antiretroviral therapy. [2006.10]
Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients. [2007.03.26]
Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. [2007]
Anti-HIV drugs. [2007]
Key reports from the XV International HIV Drug Resistance Workshop 2006. [2007]
Predicting HIV care costs using CD4 counts from clinical trials. [2007.09]
The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. [2007.10]
The clinical pharmacology of antiretrovirals in development. [2006.06]
Antiretroviral treatment of HIV infection: Swedish recommendations 2007. [2007]
Development of therapeutics for AIDS: structure-based molecular targeting. [2007.08]
Gateways to clinical trials. [2008.01]
Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection. [2008.01]
[New therapeutic options in protracted HIV-infected patients with virological failure] [2008.01.26]
Drug interactions between HIV protease inhibitors and acid-reducing agents. [2008]
[Epidemiology of genotypic resistance of HIV-1 in Valencia. A 4-year study] [2007.09]
Gateways to clinical trials. [2007.10]
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir. [2008.02]
Gateways to clinical trials. [2007.09]
How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection. [2007.10.15]
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. [2007.12]
Tipranavir: a new option for the treatment of drug-resistant HIV infection. [2007.09.15]
Induction effects of ritonavir: implications for drug interactions. [2008.07]
New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. [2008.07]
Development of an implantable infusion pump for sustained anti-HIV drug administration. [2008.05.01]
Dog model with implanted pump to test boosters for antiretroviral medication. [2008.05.01]
Evaluating the potency of HIV-1 protease drugs to combat resistance. [2008.05.15]
A frontal mucocele caused by an immune reconstitution inflammatory syndrome in a patient with HIV infection. [2008.09]
Emerging resistance profiles of newly approved antiretroviral drugs. [2008.10]
Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. [2008.11]
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. [2009.08.25]
|
